Patient with Asthma Suffering from Treatment-Related Conjunctivitis: Clinical Consults

Program Overview

We thank our learners for submitting their difficult asthma cases! Our faculty have reviewed the submissions and have come together to discuss assessment/management strategies for the selected case. Tune in to find out what our pulmonologists and allergist/immunologist have to say.

Credit Expired
CE Credit Expired
Expires: February 27, 2021

Target Audience

The target audience for this activity is US-based pulmonologists, allergists, and immunologists, as well as NPs and PAs who diagnosis and manage difficult-to-treat and severe asthma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with poorly-controlled or difficult-to-treat asthma who are eligible for step-up therapies, including new and emerging biologics
  • Incorporate new and emerging targeted biologics into the management of patients with severe or poorly-controlled asthma, when appropriate

Activity Faculty

Reynold A. Panettieri, Jr, MD

Reynold Panettieri, MD

Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
Emeritus Professor, Medicine
New Brunswick, NJ

Michael E. Wechsler, MD, MMSc

Michael E. Wechsler, MD, MMSc

Co-Director, The Cohen Family Asthma Institute
Professor, Department of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

Jonathan Corren, MD

Jonathan Corren, MD

Clinical Associate Professor, Medicine and Pediatrics Division of Clinical Immunology and Allergy
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA

Supporter Statement

Provider Statement

Disclosure of Financial Relationships

Faculty

Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources